Phase 2 N=57 Chronic Evaluation of Respicardia Therapy
Sleep Disordered Breathing · Cheyne Stokes Respiration · Periodic Breathing
Primary: AHI Change From Baseline at 3 Months — -27.1 events/hour — p=<.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=121 Effect of Febuxostat on Blood Pressure
Hypertension
Primary: Change From Baseline in 24-hour Mean Systolic Blood Pressure (SBP) Measured by Ambulatory Blood Pressure Monitoring at Week 6 — 142.3; 139.5; -3.4; -3.7 millimeters of…
Phase 2 N=40 Effect of Albendazole Dose on Treatment of Lymphatic Filariasis
Lymphatic Filariasis
Primary: Microfilarial Counts at 1 Year — 0; 0; 0 MF/ML — p=<0.2
Phase 2 N=50 Pharmacokinetics, Efficacy, and Safety of Perampanel Oral Suspension on Seizure Frequency in Pediatric Subjects Maintained on One to Three Stable Antiepileptic Drugs
Central Nervous System
Primary: Apparent Clearance (CL/F) of Perampanel [Core Study] — 0.732; 0.956; 1.73; 1.92 Liter per hour
Phase 2 N=54 Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604)
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Leukemia, Myeloid, Acute · Burkitt Lymphoma
Primary: Overall Survival at 180 Days From the Time of Transplant — 73.5; 54.0 percentage of participants
Phase 2 N=59 Pharmacokinetics of LCP-Tacro in Stable Liver Transplant Patients
Liver Failure
Primary: Evaluation of Steady State Tacrolimus Trough Levels (C24). — 6.72 ng/mL
Phase 2 N=93 Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene Mutation
Cystic Fibrosis
Primary: Safety and Tolerability Based on Adverse Events (AEs) — 17; 16; 15; 16 participants
Phase 2 N=23 Phase II A Trial of Curcumin Among Patients With Prevalent Subclinical Neoplastic Lesions (Aberrant Crypt Foci)
Healthy, no Evidence of Disease · Tobacco Use Disorder
Primary: Baseline in Prostaglandin E2 (PGE2) Within Aberrant Crypt Foci (ACF) — 1.1; 3.4 µg/g protein
Phase 2 N=134 A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients
Carcinoma, Hepatocellular
Primary: Maximum Tolerated Dose in Phase I — 200; 200 mg
Phase 2 N=59 Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
Primary: Overall Participant Response Rate: Percentage of Participants With Complete + Partial Response According to Revised National Cancer Institute-sponsored Working Group…
Phase 2 N=41 Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer
Prostate Cancer
Primary: Prostate-Specific Antigen (PSA) Progression at 1 Year After Completing Androgen Deprivation Therapy (ADT) — 98 percentage of participants with data
Phase 2 N=191 Clinical Study Investigating the Efficacy of a Mouthwash in Providing Long Term Relief From Dentinal Hypersensitivity
Dentin Sensitivity
Primary: Mean Change From Baseline in Schiff Sensitivity Score at Week 8 — -1.47; -0.37 Score on scale — p=0.0001
Phase 2 N=650 Efficacy Against TB Disease, Safety, and Immunogenicity of MVA85A/AERAS-485 in HIV-Infected Adults (C-030-485)
Tuberculosis · HIV Infections
Primary: Percentage of Participants With Adverse Events — 96.0; 99.1 percentage of participants with an AE
Phase 2 N=85 Inositol in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia
Non-small Cell Lung Cancer · Squamous Lung Dysplasia
Primary: Percentage of Participants With Response Determined by Change in the Histologic Grade of Bronchial Dysplasia as Measured by Mucosal Biopsy Samples on…
Phase 2 N=36 In Vivo Assessment of Silver Biomaterial Nano-Toxicity
Healthy
Primary: Change in Sodium Blood Levels — -0.1; 0.2 mmol/L